drugset / Trial / NCT00741468

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

NCT00741468

Phase 1 Completed 18 enrolled Repros Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess possible drug-drug interactions with specific isoenzymes over a total study duration of 6-8 weeks. Blood samples collected pre and post-dose, and urine samples collected post dose will be analyzed.

Timeline

Start
2008-07
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule 200 mg Oral
Subject Dextromethorphan Unknown 30 mg Oral
Subject Midazolam Small molecule 2 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral
Subject Telapristone Acetate Other / unclassified 50 mg
Subject Tolbutamide Small molecule 250 mg Oral

Indications

No indication recorded.